Podcast: Biopharma’s evolving relationships with CDMOs
M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics. The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolv ...
As pharma’s gene therapy pipeline matures, Catalent plans to invest more in the sector to meet high viral vector demand and advance growth.
...
Pfizer says it is ceasing all future investment to build manufacturing capacity in Russia due to Vladimir Putin’s war against Ukraine.
Putin ...
Astorg Partners has signed an agreement with International Chemical Investors Group (ICIG) to acquire CDMO CordenPharma.
According to French ...
Repligen has tweaked its guidance in the wake of diminishing COVID-related orders but remains positive going forward due to a “very strong orde ...
Recent Tweets
-
Great panel discussion about the security of supply chains at the BPI Theatre #BPIWest https://t.co/rMFdNpHjhM
2 years ago
-
We’re at #BPIWEST, 2023!
2 years ago
-
What a great event #cphi2022 - see you in Barcelona next year!
2 years ago
-
We’re here & ready for the second day at #CPHI in Frankfurt!
2 years ago
